Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non- metastatic muscle invasive urothelial bladder cancer

Basit Öğe Kaydı
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorEbinç, Senar
dc.contributor.authorTunç, Sezai
dc.contributor.authorOruç, Zeynep
dc.contributor.authorKüçüköner, Mehmet
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.date.accessioned2025-02-22T14:13:28Z
dc.date.available2025-02-22T14:13:28Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: In this study, we aimed to investigate the factors that may have the potential to predict pathological complete response (pCR) with platinum-based neoadjuvant chemotherapy (NAC) in non-metastatic muscle-invasive bladder cancer (MIBC). Methods: Our study included 46 patients diagnosed with non-metastatic MIBC, who applied to Dicle University Medical Oncology Clinic between 2016-2019 years and received NAC. Age, gender, ECOG performance score, tumor grade, pathological tumor (pT) stage, clinical lymph node (cN) status, localization of the primary tumor in the bladder, presence of comorbid diseases, renal failure status, hydronephrosis, and NAC regimens were analyzed. Results: Of the total 46 patients included in the study, 42 (81.3%) were male and 4 (8.7%) were female. The median age at diagnosis was 61.5 (34-77) years. In the group of patients aged <65 years, pCR was achieved in 9 patients (33.3%) and pCR was not achieved in 18 patients. The rate of pCR after NAC in the patient group aged <65 years was higher than in the age ≥65 group, which was statistically significant (p: 0.03). While the median disease-free survival (DFS) was not reached in the pCR arm, the median DFS was calculated as 26 months (95% CI: 4.6-47.3) in the non-pCR arm (Log Rank p=0.23). The mean overall survival (OS) value in the pCR arm was 126 months (95% CI: 106.5- 145.4) and the mean OS value in the non-pCR arm was 53.5 months (95% CI: 44.2-62.9) (Log Rank p=0.05). Conclusion: In our study, age <65 years was found to be an independent prognostic factor for pCR in the neoadjuvant treatment of non-metastatic MIBC. Mean OS was better in patients who achieved pCR.en_US
dc.identifier.doi10.54307/NWMJ.2023.41275
dc.identifier.endpage146en_US
dc.identifier.issn2757-7724
dc.identifier.issue3en_US
dc.identifier.startpage139en_US
dc.identifier.trdizinid1265753en_US
dc.identifier.urihttps://doi.org/10.54307/NWMJ.2023.41275
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1265753
dc.identifier.urihttps://hdl.handle.net/11468/29984
dc.identifier.volume3en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.relation.ispartofNorthwestern Medical Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_TR_20250222
dc.subjectBladder canceren_US
dc.subjectneoadjuvant chemotherapyen_US
dc.subjectpathological complete responseen_US
dc.titleFactors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non- metastatic muscle invasive urothelial bladder canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu